Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 5/20 | 0.63 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.34 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044922 | 0.93 | MAPKAPK5 (0.62) | MAPKAPK5KDM1AZAP70ROCK2MITF | |
| SCHEMBL1044506 | 0.91 | MAPKAPK5 (0.60) | MAPKAPK5KDM1AZAP70GAAMAPT | |
| SCHEMBL1043477 | 0.90 | MAPKAPK5 (0.76) | MAPKAPK5KDM1AAOC3EGFRRAD52 | |
| SCHEMBL1045465 | 0.87 | MAPKAPK5 (0.60) | MAPKAPK5KDM1AZAP70GAAMAPT | |
| SCHEMBL1047036 | 0.87 | MAPKAPK5 (0.62) | MAPKAPK5ROCK2FGFR1TTBK1TTBK2 | |
| SCHEMBL10134456 | 0.85 | MAPKAPK5 (0.63) | MAPKAPK5ZAP70MT-CO2GAAMAPT | |
| SCHEMBL1047106 | 0.84 | MAPKAPK5 (0.60) | MAPKAPK5ROCK2TTBK1TTBK2LRRK2 | |
| SCHEMBL1046099 | 0.83 | MAPKAPK5 (0.58) | MAPKAPK5ROCK2FGFR1 | |
| SCHEMBL1045305 | 0.83 | MAPKAPK5 (0.58) | MAPKAPK5ZAP70ROCK2FGFR1LRRK2 | |
| SCHEMBL1082113 | 0.83 | MAPKAPK5 (0.58) | MAPKAPK5ZAP70ROCK2FGFR1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | claimed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | claimed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| EP-2086540-B8 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 15/4885KDM1A 2801/4885ZAP70 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.